RET fusions drive around 1 to 2% of all lung cancers. For years, treatment options were limited. That has changed. New data from ASCO 2026 show that targeted therapies now span multiple stages of RET fusion-positive lung cancer, with next-generation options already in development. Lung Cancer Europe explains the science, the treatments, and what to ask your oncologist.

Last week, two things converged. The world's largest oncology conference brought thousands of researchers to Chicago. And Nature published an article declaring lung cancer in women a distinct disease. The timing was not coincidental.

Scientists at the Francis Crick Institute and UCL have identified 14 proteins in blood that can predict lung cancer more than five years before diagnosis. The research, published in Cell on 4 June 2026, also points toward a prevention strategy. Here is what it found and why it matters for people affected by lung cancer across Europe.

Lung Cancer Europe President Debra Montague is among more than 490 healthcare experts, researchers, academics, and patient advocates calling for a dedicated, ring-fenced health budget in the EU’s next long-term budget. Here is what the MFF 2028-2034 negotiations mean for people living with lung cancer across Europe.

Tobacco is the single largest preventable cause of lung cancer in Europe. But lung cancer can affect anyone, including people who have never smoked. On World No Tobacco Day 2026, Lung Cancer Europe calls for stronger EU tobacco regulation to protect young people from targeted marketing, and compassionate support for people who want to quit.